VR Logo

Oric Pharmaceuticals Inc. (ORIC) download report


Healthcare | Biotechnology & Pharma Research

Oric Pharmaceuticals Inc. (ORIC) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.

IPO Date: 24-Apr-2020

Co-Founder, Independent Chairman & Member of Scientific Advisory Board: Dr. Richard A. Heyman Ph.D.

Pres, CEO & Director: Dr. Jacob M. Chacko M.B.A., M.D.

Listing: NASDAQ: ORIC

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.oricpharma.com

Key Facts

Market cap: $172.52 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-85.37 Mln

Cash: $234.62 Mln

Total Debt: $2.02 Mln

Insider's Holding: 3.93%

Liquidity: Low

52 Week range: $2.62 - 26.70

Shares outstanding: 39,478,200

5 Years Aggregate:

  • CFO: $-169.86 Mln
  • EBITDA: $-200.20 Mln
  • Net Profit: $-200.66 Mln

Stock Performance

Time Period Oric Pharmaceuticals (ORIC) S&P BSE Sensex S&P Small-Cap 600
YTD-72.04-9.49-17.79
1 month26.07-2.87-2.72
3 months-20.19-8.59-12.17
1 Year-77.090.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Oric Pharmaceuticals (ORIC) S&P Small-Cap 600 S&P BSE Sensex
2021-56.5725.2721.99